Merck
MRK
#51
Rank
NZ$508.40 B
Marketcap
NZ$205.85
Share price
-0.43%
Change (1 day)
54.29%
Change (1 year)

P/E ratio for Merck (MRK)

P/E ratio as of June 2026 (TTM): 33.5

According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.4772. At the end of 2025 the company had a P/E ratio of 14.4.

P/E ratio history for Merck from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202514.4-0.02%
202414.4-97.87%
20236793674.95%
202218.034.71%
202113.4-44.9%
202024.227.46%
201919.0-25.19%
201825.4-44.27%
201745.6116.87%
201621.0-11.64%
201523.8152.83%
20149.42-58.32%
201322.686.02%
201212.16.11%
201111.4

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
27.3-18.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.1-36.97%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.5-41.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
24.7-26.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
40.3 20.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
23.3-30.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
17.0-49.15%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
15.6-53.35%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
13.2-60.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
24.5-26.78%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.